Natera, Inc. released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024, indicating strong financial performance. The company expects 2024 revenues to increase by approximately 56% compared to 2023.
This projected revenue figure is approximately $53 million above the top end of Natera's previously issued financial outlook, signaling better-than-expected growth. The preliminary results were shared ahead of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
In addition to the financial update, Natera also presented details on its innovation roadmap for oncology, highlighting advancements in molecular residual disease (MRD) and early cancer detection. This strategic outline provides insight into future growth drivers and product development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.